Order a paperback or Kindle Edition or e-book of "My Voice: A Physician's Personal Experience with Throat Cancer," the complete 282 page story of Dr. Brook's diagnosis, treatment, and recovery from throat cancer.
Order a paperback or Kindle Edition or e-book of "The Laryngectomee Guide," the 170 page practical guide for laryngectomees. To obtain a free paperback copy fill this form and mail it to J. Harrison 11390 W. Theo W. Allis, WI 53214, or fax it to 414 227 9033. The Guide can also be requested by emailing to email@example.com
Tuesday, July 19, 2016
Laryngeal Carcinoma patients’ outcomes can be improved by adding Cetuximab to radiotherapy
Laryngeal preservation and laryngectomy-free survival of patients with hypopharyngeal or laryngeal carcinoma, can be improved by addition of cetuximab to radiotherapy according to a recent study published by Bonner et al. from the University of Alabama at Birmingham.
The authors examined the rates of laryngeal preservation and laryngectomy-free survival in a randomized trial involving patients with cancer of the larynx or hypopharynx. A total of 168 patients from 73 centers in the US and 14 other countries were randomized to cetuximab and radiotherapy (CRT; 90 patients) or radiotherapy alone (78 patients).
The researchers found the rates of laryngeal preservation (no need for laryngectomy) were 87.9 and 85.7% for CRT and radiotherapy alone, respectively, at two years. Median overall survival was 27 months in the CRT group and 21 months in the radiotherapy-alone group. There were no differences observed in overall quality of life, need for a feeding tube, or speech.